Localised inhibition of coagulation limits acute complement mediated damage in high risk renal transplantation

Organ Pretreatment With Cytotopic Endothelial Localizing Peptides to Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal Hemoreperfusion Models

“…The increasing use of ECD and DCD organs to expand donor pools means any approach that could ameliorate micro-vascular dysfunction and improve organ perfusion at the reperfusion stage is in high clinical demand. TLN is a novel membrane localising 'cytotopic' anti-coagulant construct that has proven efficacy in improving graft function in murine kidney transplantation models [26]. This is the first study of the pretreatment of large animal organs with this cytotopic anti-coagulant agent using HMP as a delivery vehicle, and further assessing the benefits of this pre-treatment using a NHRP challenge.…”